Novartis AG ADR (NVS)vsOculis Holding AG Ordinary shares (OCS)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
OCS
Oculis Holding AG Ordinary shares
$27.48
+3.89%
HEALTHCARE · Cap: $1.57B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 4718666% more annual revenue ($56.58B vs $1.20M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
OCS
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Intrinsic value data unavailable for OCS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Revenue surging 13600.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : OCS
The strongest argument for OCS centers on Revenue Growth, Debt/Equity. Revenue growth of 13600.0% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : OCS
The primary concerns for OCS are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while OCS is a hypergrowth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
OCS is growing revenue faster at 13600.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 29/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Oculis Holding AG Ordinary shares
HEALTHCARE · BIOTECHNOLOGY · USA
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug, Switzerland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?